Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Details)

v3.20.4
INCOME TAXES (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Deferred tax assets      
Net operating loss carryforwards $ 240,767 $ 240,157  
Orphan drug and research and development credits 64,252 59,603  
Deferred compensation 7,760 8,817  
Lease liabilities 4,399 6,989  
Capitalized Inventory 34    
Capitalized research and development expenses   2,282  
Other, net 3,170 529  
Deferred tax liabilities      
Operating lease right-of-use asset (4,084) (6,719)  
Others (537)    
Total net deferred tax assets 315,761 311,658  
Less: valuation allowance (315,761) (311,658)  
Deferred tax assets, net of allowance  
Reconciliation of the statutory federal income tax rate to the effective tax rate      
Federal statutory tax rate (as a percent) (21.00%) (21.00%) (21.00%)
State, Net of Federal Benefit (as a percent) 0.10% 0.10%  
Valuation allowance (as a percent) 24.40% 21.70% 16.30%
Stock compensation (as a percent) 4.70% 2.80% 8.20%
Orphan drug and research and development credits (as a percent) (12.70%) (5.10%) (3.70%)
Other, net (as a percent) 4.60% 1.50% 0.20%
Effective tax rate (as a percent) 0.10% 0.00% 0.00%